1. Home
  2. SKYE vs NCV Comparison

SKYE vs NCV Comparison

Compare SKYE & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • NCV
  • Stock Information
  • Founded
  • SKYE 2012
  • NCV 2003
  • Country
  • SKYE United States
  • NCV United States
  • Employees
  • SKYE N/A
  • NCV N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • NCV Finance Companies
  • Sector
  • SKYE Health Care
  • NCV Finance
  • Exchange
  • SKYE Nasdaq
  • NCV Nasdaq
  • Market Cap
  • SKYE 294.2M
  • NCV 300.0M
  • IPO Year
  • SKYE N/A
  • NCV N/A
  • Fundamental
  • Price
  • SKYE $6.51
  • NCV $3.34
  • Analyst Decision
  • SKYE Strong Buy
  • NCV
  • Analyst Count
  • SKYE 4
  • NCV 0
  • Target Price
  • SKYE $19.25
  • NCV N/A
  • AVG Volume (30 Days)
  • SKYE 428.5K
  • NCV 405.1K
  • Earning Date
  • SKYE 01-01-0001
  • NCV 01-01-0001
  • Dividend Yield
  • SKYE N/A
  • NCV 12.48%
  • EPS Growth
  • SKYE N/A
  • NCV N/A
  • EPS
  • SKYE N/A
  • NCV N/A
  • Revenue
  • SKYE N/A
  • NCV N/A
  • Revenue This Year
  • SKYE N/A
  • NCV N/A
  • Revenue Next Year
  • SKYE N/A
  • NCV N/A
  • P/E Ratio
  • SKYE N/A
  • NCV N/A
  • Revenue Growth
  • SKYE N/A
  • NCV N/A
  • 52 Week Low
  • SKYE $1.44
  • NCV $2.84
  • 52 Week High
  • SKYE $19.41
  • NCV $3.59
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 36.55
  • NCV 60.54
  • Support Level
  • SKYE $5.48
  • NCV $3.17
  • Resistance Level
  • SKYE $6.93
  • NCV $3.36
  • Average True Range (ATR)
  • SKYE 1.11
  • NCV 0.03
  • MACD
  • SKYE -0.09
  • NCV 0.01
  • Stochastic Oscillator
  • SKYE 33.69
  • NCV 86.84

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

Share on Social Networks: